Valuation: NEOVACS

Market Cap 4.09K 4.66K 3.78K 3.49K 6.61K 446K 6.74K 45.38K 17.63K 218K 17.51K 17.12K 758K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -229K -186K -171K -325K -21.94M -332K -2.23M -867K -10.74M -861K -842K -37.27M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 231K
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.21%+420.77%+597.43% 40.49B
-2.29%+3.83%+23.48%+56.80% 34.35B
-2.13%+0.29%+23.91%-7.13% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.51% - - 16.58B
-2.62%-2.13%+64.96%+120.02% 15.6B
-2.17%+6.65%+104.31%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -1.19%+3.99%+81.90%+116.63% 27.39B
Weighted average by Cap. -1.27%+4.37%+93.80%+134.43%

Financials

2023 2024
Net sales 533K 608K 492K 455K 863K 58.23M 880K 5.92M 2.3M 28.5M 2.28M 2.23M 98.92M 434K 495K 401K 370K 702K 47.37M 716K 4.82M 1.87M 23.18M 1.86M 1.82M 80.48M
Net income -8.74M -9.97M -8.07M -7.46M -14.14M -955M -14.42M -97.04M -37.71M -467M -37.44M -36.61M -1.62B -32.91M -37.53M -30.39M -28.08M -53.22M -3.59B -54.29M -365M -142M -1.76B -141M -138M -6.1B
Net Debt -237K -270K -218K -202K -382K -25.82M -390K -2.62M -1.02M -12.63M -1.01M -990K -43.86M -205K -234K -189K -175K -332K -22.39M -338K -2.28M -884K -10.96M -878K -859K -38.03M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-